Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 10/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.36 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.36 |
| ▸ | USP7 | Q93009 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6082788 | 0.76 | CRHR1 (0.39) | CRHR1USP7TLR8 | |
| SCHEMBL6821651 | 0.70 | LNPEP (0.35) | CRHR1USP7TLR8 | |
| SCHEMBL15698765 | 0.67 | DRD1 (0.46) | — | |
| SCHEMBL2789977 | 0.66 | P2RX3 (0.32) | P2RX3P2RX2 | |
| SCHEMBL6074920 | 0.66 | ALOX5AP (0.50) | TLR8 | |
| SCHEMBL17178251 | 0.65 | CYP11B1 (0.50) | CRHR1 | |
| SCHEMBL17178230 | 0.65 | CYP1A2 (0.48) | — | |
| SCHEMBL17178249 | 0.65 | NPC1 (0.51) | CRHR1TLR8 | |
| SCHEMBL26597794 | 0.65 | NPC1 (0.44) | TLR8 | |
| SCHEMBL30741303 | 0.65 | NPC1 (0.44) | TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067658-B2 | Pyridino and pyrimidino pyrazinones | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-27 | — | — | US | disclosed |
| US-20040082784-A1 | Pyridino and pyrimidino pyrazinones | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-04-29 | — | — | US | disclosed |
| WO-2004031189-A1 | PYRIDINO AND PYRIMIDINO PYRAZINONES FOR TREATMENT OF ANXIETY AND DEPRESSION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082784-A1 | Pyridino and pyrimidino pyrazinones | CRHR1, CRHR2, CRH | CRHR1 1/4885P2RX3 122/4885P2RX2 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.